Claim 20% Off With Code ONLINE20 – Explore Market Reports Covering Trade Trends, Regulatory Changes, and Growth Insights
How Is the Cardiotonic Agents Market Growth Forecast from 2025 to 2029?
The cardiotonic agents market size has grown rapidly in recent years. It will grow from $2.78 billion in 2024 to $3.11 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to increasing prevalence of heart failure, a growing geriatric population, rising incidence of coronary artery disease, increasing adoption of sedentary lifestyles, and a growing burden of hypertension and diabetes.
The cardiotonic agents market size is expected to see rapid growth in the next few years. It will grow to $4.95 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to rising cardiovascular mortality rates, rising clinical trials focusing on improved cardiotonic formulations, rising public-private partnerships in cardiovascular drug development, growing hospital admissions due to cardiac complications, and growing demand for personalized cardiovascular medicine. Major trends in the forecast period include developing peptide-based cardiotonic agents, developing dual-mechanism drugs, integrating pharmacogenomics, innovating injectable depot formulations, and innovating combination therapies.
Claim your free report sample now:
What Are the Key Growth Factors Supporting the Cardiotonic Agents Market Expansion?
The rise in prevalence of cardiovascular diseases is expected to propel the growth of the cardiotonic agents market going forward. Cardiovascular diseases (CVDs) refer to a group of disorders that affect the heart and blood vessels, including conditions such as coronary artery disease, heart failure, arrhythmias, and stroke. The rise in cardiovascular diseases is primarily due to unhealthy diets high in saturated fats, trans fats, salt, and added sugars, which contribute to obesity, high blood pressure, and elevated cholesterol levels. Cardiotonic agents improve the efficiency and contraction strength of the heart muscle, thereby supporting better blood circulation and reducing symptoms in various cardiovascular diseases. For instance, in December 2023, according to the Australian Institute of Health and Welfare, an Australia-based government agency, doctor-certified deaths due to coronary heart disease (CHD) in Australia increased from 14,100 in 2021 to 14,900 in 2022. Therefore, the rise in prevalence of cardiovascular diseases is driving the growth of the cardiotonic agents market.
What Segments Are Covered in the Cardiotonic Agents Market Report?
The cardiotonic agents market covered in this report is segmented –
1) By Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types
2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations
3) By Dosage Form: Tablet, Solution, Other Dosage Forms
4) By Application: Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Digitalis Glycoside: Digoxin, Digitoxin, Lanatoside C
2) By Phosphodiesterase Inhibitors: Milrinone, Enoximone, Amrinone
3) By Cardioprotectants: Coenzyme Q10, Dexrazoxane, Trimetazidine
4) By Sympathomimetic Agents: Dobutamine, Dopamine, Norepinephrine
5) By Other Drug Types: Levosimendan, Omecamtiv Mecarbil, Cilostazol
What Are the Key Trends Shaping the Cardiotonic Agents Market?
Major companies operating in the cardiotonic agents market are focusing on developing innovative products, such as short-term inotropic drugs, to enhance cardiac performance in acute heart failure and cardiogenic shock. Short-term inotropic drugs are medications used to temporarily enhance the heart's ability to contract, thereby improving cardiac output. For instance, in June 2023, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, launched Dobutamine Injection, USP, in a 250 mg/20 mL vial. This injection is used for short-term inotropic support in adults experiencing cardiac decompensation due to reduced heart contractility, commonly caused by heart disease or following cardiac surgery. It works by stimulating beta-1 receptors, which enhances heart muscle contractility and cardiac output with a rapid onset (1–2 minutes). The injection is administered intravenously and is typically given in a hospital setting with close monitoring.
Who Are the Key Players Driving the Cardiotonic Agents Market?
Major companies operating in the cardiotonic agents market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, Deccan Nutraceuticals Pvt. Ltd.
Get the full cardiotonic agents market report here:
How Does Cardiotonic Agents Market Growth Vary Across Major Regions?
North America was the largest region in the cardiotonic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiotonic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment